We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pandemic Impacts Seen in FDA’s Offices of Pharmaceutical Quality, Generic Drugs
Pandemic Impacts Seen in FDA’s Offices of Pharmaceutical Quality, Generic Drugs
The latest annual reports from the FDA’s Office of Pharmaceutical Quality (OPQ) and its Office of Generic Drugs (OGD) both highlight the impact of the COVID-19 pandemic on their activities in the past year.